SenesTech's Financing Move: $1.1 Million From Warrant Exercise, New Deals Loom

Comments
Loading...
Zinger Key Points

SenesTech, Inc. SNES shares are trading lower on Monday. The company inked deals to immediately exercise outstanding warrants for a total of 374,718 shares of common stock, originally issued on August 23, 2024, with a reduced exercise price of $2.90 per share, down from $4.35.

Additionally, the company will issue new short-term warrants. The exercise of existing warrants is expected to generate gross proceeds of approximately $1.1 million, before deducting placement agent fees and other offering expenses.

If fully exercised, the new short-term warrants could bring in potential gross proceeds of around $4.3 million. Meanwhile, there is no guarantee that any of the new short-term warrants will be exercised.

The company plans to use the net proceeds from the transaction for working capital and general corporate purposes.

The closing of this transaction is expected on or around March 11, 2025, pending stockholder approval and customary closing conditions.

Notably, in exchange for the cash exercise of existing warrants, the company will issue new unregistered short-term warrants to purchase up to 1.498 million shares of common stock at $2.90 per share in a private placement.

These warrants will be exercisable upon stockholder approval and will expire 18 months after such approval.

The company plans to report fourth-quarter results on Wednesday, March 12, 2025.

As of September 30, cash and cash equivalents stood at $2.5 million.

Price Action: SNES shares are down 18.6% at $2.45 at the last check Monday.

Read Next:

Photo via Shutterstock.

SNES Logo
SNESSenesTech Inc
$1.31-0.76%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
7.22
Growth
86.29
Quality
-
Value
77.62
Price Trend
Short
Medium
Long
Got Questions? Ask
How will SenesTech's financing affect share prices?
What impact could new warrants have on investor interest?
Which investors might consider short-term warrants now?
How could SenesTech's cash position influence future deals?
What industries might be affected by SenesTech's financing strategy?
Could private placements lead to a surge in bio-tech investments?
Which investors will be impacted by upcoming earnings announcements?
How might the stockholder approval process affect market confidence?
What are the risks associated with exercising new warrants?
Which companies might benefit from SenesTech's financing model?

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

Posted In: